FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to aqueous solutions applicable as pharmaceutical compositions of posaconazole for intravenous administration. These compositions contain a solvent, such as modified β-cyclodextrine in acidified solution, as well as a chelating agent, such as disodium edentate (ethylene diamine tetraacetate). The clinical trials have shown that a dose of the selected composition making 200 mg of posaconasole enables achieving the acceptable pharmacokinetic properties.
EFFECT: prepared pharmaceutical composition possesses physical and chemical stability.
21 cl, 8 dwg, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR, COMPOSITION OF RAS-FARNESYLT RANSFERASE INHIBITOR, PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2230062C2 |
| FORMULATIONS OF 2-IMINOBIOTINE AND USE THEREOF | 2011 |
|
RU2627460C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2667010C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2824132C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITIONS BASED ON 1,2-DIHYDROPYRIDINE COMPOUNDS | 2019 |
|
RU2824582C2 |
| ANAESTHETIC COMPOSITION | 2011 |
|
RU2574022C2 |
| INHALATION COMPOSITION CONTAINING SULFOALKYL ETHER | 2004 |
|
RU2388462C2 |
| INHALATION FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRIN AND CORTICOSTEROID | 2004 |
|
RU2390330C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND METHODS OF USING THEM | 2015 |
|
RU2731000C2 |
| INJECTABLE COMPOSITIONS BASED ON URSODEOXYCHOLIC ACID | 2020 |
|
RU2805311C1 |
